20.500.12556/RUL-166501 Glioblastoma clinical presentation, multidisciplinary management, and long-term outcomes Glioblastoma is the most aggressive brain cancer and has challenging survival outcomes despite comprehensive treatment strategies. Typical survival for newly diagnosed patients is 12–15 months with a two-year survival rate below 30%. Treatment generally includes surgical resection, radiation, and temozolomide chemotherapy. Key factors impacting prognosis include patient age, molecular markers, and the extent of tumor resection. Younger patients and those with IDH-mutant or MGMT-methylated tumors often fare better. For recurrent cases, median survival drops to about six months, with treatments offering mostly palliative benefits. Innovations like tumor-treating fields (TTFields) provide a modest survival extension. Comprehensive care also requires managing symptoms like seizures and headaches, along with psychological support for patients and caregivers to improve quality of life. Although current therapies have limited efficacy due to glioblastoma’s resistance, ongoing clinical trials and research into targeted and immunotherapies provide hope for improved outcomes in the future. glioblastoma prognosis treatment survival outcome true false true Angleški jezik Ni določen Članek v reviji 2025-01-15 14:03:14 2025-01-15 14:03:15 2025-01-16 03:54:50 0000-00-00 00:00:00 2025 0 0 17 str. issue 1, art. 146 Vol. 17 Jan. 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2025-01-01 616-006.04 2072-6694 10.3390/cancers17010146 222491907 cancers-17-00146_(2).pdf cancers-17-00146_(2).pdf 1 64C58050764A0AF70F2FEDF12F50618C 31bad712b620b79389451326de37062e7655cbb5c28c2e75a5f45d69bcc45c14 b1c64d67-d340-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=198159 https://www.mdpi.com/2072-6694/17/1/146 1 63b6d8df-d340-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=198158 Zdravstvena fakulteta 0 0 0